Related coverage linked through entity extraction aliases.
Mar 17, 2026
Merck will present late-breaking clinical data from its cardio-pulmonary pipeline at ACC.26, including positive Phase 3 results for enlicitide, an investigational oral PCSK9 inhibitor, and Phase 2 data for WINREVAIR in heart failure patients.
Mar 04, 2026
Tempus AI and Merck announced an expanded multi-year collaboration to accelerate discovery and development of precision medicine biomarkers using AI and multimodal datasets, focusing on oncology and potentially broader therapeutic areas.
Mar 02, 2026
Final analysis of Merck's Phase 3 KEYNOTE-B96 trial shows KEYTRUDA plus paclitaxel with or without bevacizumab significantly improved overall survival in platinum-resistant recurrent ovarian cancer patients, reducing death risk by 18%.
